- DCGI gives nod to Serum Institute of India to resume Oxford vaccine trial
- DCGI had ordered to suspend new recruitment for phase 2 and 3 of the trials
- DGCI has put certain conditions like taking extra care during screening
Moscow: The Russian Direct Investment Fund on Wednesday confirmed reaching an agreement to supply 100 million doses of Russian COVID-19 vaccine Sputnik V to India’s Dr. Reddy’s Laboratories.
The RDIF, Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine, Sputnik quoted the RDIF’s press release.
Deliveries could start in late 2020, the release added.
Also Read: Serum Institute To Produce COVID-19 Vaccine Candidate Developed By Oxford University, Will Be Called Covishield In India
GV Prasad, Co-Chairman and Managing Director of Dr. Reddy said that the Phase I and II trials results have shown promise, and the company will be conducting Phase III trials in India to meet the requirements of the Indian regulators.
We are pleased to partner with RDIF to bring the vaccine to India. Phase I and II results have shown promise, and we will be conducting Phase III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India, Dr. Reddy’s Co-Chairman and Managing Director GV Prasad said, as quoted in the press release.
The RDIF is pleased to reach the agreement with the Indian company, the RDIF CEO Kirill Dmitriev said.
Also Read: AstraZeneca Vaccine Trial Pause A ‘Wake-Up Call’, Says WHO
Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst most severely impacted countries from the novel coronavirus and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19. RDIF partners will receive an effective and safe drug to fight the coronavirus, he added.
Last week, the Russian Health Ministry announced that the first batch of Sputnik V vaccine against COVID-19 has been released into civil circulation.
The Russian health ministry registered the first vaccine against COVID-19, named Sputnik V, on August 11.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.